The antitumor activity of Momordica anti-human immunodeficiency virus protein of 30 kDa (MAP30) has been proved. However, the role of MAP30 on tumor metastasis has not yet been identified. For this purpose, we investigated this effect and underlying mechanism of MAP30 in bladder cancer (BC). Here, we reported that MAP30 significantly inhibited the cell proliferation and clone formation of 5637 and T24 cells in vitro by promoting apoptosis and cell cycle arrest. We also found MAP30 inhibited cell migration and invasion by suppressing the epithelial/mesenchymal transition (EMT) process. Moreover, the Affymetrix GeneChip assay revealed that MAP30 significantly changed gene expression profile in T24 cells, especially the genes in cell cycle regulation pathways. After the Ingenuity Pathway Analysis, we predicted that NUPR1 was the most important upstream regulator. Subsequently, we verified that the AKT and EMT signaling pathways were inhibited by MAP30 treatment in T24 cells. In conclusion, MAP30 treatment inhibited the progression of human BC, especially cell migration and invasion through suppressing AKT pathways.
Get full access to this article
View all access options for this article.
References
1.
AntoniS., FerlayJ., SoerjomataramI., ZnaorA., JemalA., and BrayF. (2017). Bladder cancer incidence and mortality: a global overview and recent trends. Eur Urol, 71, 96–108.
2.
BrennanV.C., WangC.M., and YangW.H. (2012). Bitter melon (Momordica charantia) extract suppresses adrenocortical cancer cell proliferation through modulation of the apoptotic pathway, steroidogenesis, and insulin-like growth factor type 1 receptor/RAC-alpha serine/threonine-protein kinase signaling. J Med Food, 15, 325–334.
3.
ChenT., YouY., JiangH., and WangZ.Z. (2017). Epithelial-mesenchymal transition (EMT): a biological process in the development, stem cell differentiation, and tumorigenesis. J Cell Physiol, 232, 3261–3272.
4.
ChenW., ZhengR., BaadeP.D., ZhangS., ZengH., BrayF., et al. (2016). Cancer statistics in China, 2015. CA Cancer J Clin, 66, 115–132.
5.
DengY.Y., YiY., ZhangL.F., ZhangR.-F., ZhangY., WeiZ.-C., et al. (2014). Immunomodulatory activity and partial characterisation of polysaccharides from Momordica charantia. Molecules 19,13432.
6.
FanJ.M., LuoJ., XuJ., ZhuS., ZhangQ., GaoD.-F., et al. (2008). Effects of recombinant MAP30 on cell proliferation and apoptosis of human colorectal carcinoma LoVo cells. Mol Biotechnol, 39, 79–86.
7.
FanX., HeL., MengY., LiG., LiL., and MengY. (2015). Alpha-MMC and MAP30, two ribosome-inactivating proteins extracted from Momordica charantia, induce cell cycle arrest and apoptosis in A549 human lung carcinoma cells. Mol Med Rep, 11, 3553–3558.
8.
FangE.F., ZhangC.Z., WongJ.H., ShenJ.Y., LiC.H., and NgT.B. (2012). The MAP30 protein from bitter gourd (Momordica charantia) seeds promotes apoptosis in liver cancer cells in vitro and in vivo. Cancer Lett, 324, 66–74.
9.
GonzalezD.M., and MediciD. (2014). Signaling mechanisms of the epithelial-mesenchymal transition. Sci Signal 7,re8.
10.
HanahanD., and WeinbergR.A. (2011). Hallmarks of cancer: the next generation. Cell 144,646.
11.
HsiehC.H., ChenG.C., ChenP.H., WuT.F., and ChaoP.M. (2013). Altered white adipose tissue protein profile in C57BL/6J mice displaying delipidative, inflammatory, and browning characteristics after bitter melon seed oil treatment. PLoS One 8,e72917.
12.
HsuC., TsaiT.H., LiY.Y., WuW.H., HuangC.J., and TsaiP.J. (2012). Wild bitter melon (Momordica charantia Linn. var.abbreviata Ser.) extract and its bioactive components suppress Propionibacterium acnes-induced inflammation.Food Chem, 135, 976–984.
13.
JainV., PareekA., PaliwalN., RatanY., JaggiA.S., and SinghN. (2014). Antinociceptive and antiallodynic effects of Momordica charantia L. in tibial and sural nerve transection-induced neuropathic pain in rats. Nutr Neurosci, 17, 88–96.
14.
Lee-HuangS., HuangP.L., ChenH.C., HuangP.L., BourinbaiarA., HuangH.I., et al. (1995). Anti-HIV and anti-tumor activities of recombinant MAP30 from bitter melon. Gene, 161, 151–156.
15.
Lee-HuangS., HuangP.L., HuangP.L., BourinbaiarA.S., ChenH.C., KungHF. (1995). Inhibition of the integrase of human immunodeficiency virus (HIV) type 1 by anti-HIV plant proteins MAP30 and GAP31. Proc Natl Acad Sci U S A 92,8818.
16.
Lee-HuangS., HuangP.L., NaraP.L., ChenH.C., KungH.F., HuangP., et al. (1990). MAP 30: a new inhibitor of HIV-1 infection and replication. FEBS Lett, 272, 12–18.
17.
Lee-HuangS., HuangP.L., SunY.T., ChenH.C., KungH.F., HuangP.L., et al. (2000). Inhibition of MDA-MB-231 human breast tumor xenografts and HER2 expression by anti-tumor agents GAP31 and MAP30. Anticancer Res, 20,(2A),653–659.
18.
LiC.J., TsangS.F., TsaiC.H., TsaiH.Y., ChyuanJ.H., and HsuH.Y. (2012). Momordica charantia extract induces apoptosis in human cancer cells through caspase- and mitochondria-dependent pathways. Evid Based Complement Alternat Med 2012,261971.
19.
LiS.T., ChenN.N., QiaoY.B., ZhuW.L., RuanJ.W., and ZhouX.Z. (2016). SC79 rescues osteoblasts from dexamethasone though activating Akt-Nrf2 signaling. Biochem Biophys Res Commun, 479, 54–60.
20.
LiuJ., ChenY., ShuaiS., DingD., LiR., and LuoR. (2014). TRPM8 promotes aggressiveness of breast cancer cells by regulating EMT via activating AKT/GSK-3beta pathway. Tumour Biol, 35, 8969–8977.
21.
MengJ., ZhangX.T., LiuX.L., FanL., LiC., SunY., et al. (2016). WSTF promotes proliferation and invasion of lung cancer cells by inducing EMT via PI3K/Akt and IL-6/STAT3 signaling pathways. Cell Signal, 28, 1673–1682.
22.
NicolasE., GoodyerI.D., TaraschiT.F. (1997). An additional mechanism of ribosome-inactivating protein cytotoxicity: degradation of extrachromosomal DNA. Biochem J, 327, 413–417.
23.
QianS., SunL., LiJ., WuJ., HuG., HanY., et al. (2016). MAP30 inhibits autophagy through enhancing acetyltransferase p300 and induces apoptosis in acute myeloid leukemia cells. Oncol Rep, 35, 3705–3713.
24.
Raghu KalluriR.A.W. (2009). The basics of epithelial-mesenchymal transition. J Clin Invest 119,1420.
25.
SinghD.K., UpadhyayA., and AgrahariP. (2015). A review on salient pharmacological features of Momordica charantia. Int J Pharmacol, 11, 405–413.
26.
SunY., HuangP.L., LiJ.J., HuangQ.Y., ZhangL., HuangP.L., et al. (2001). Anti-HIV agent MAP30 modulates the expression profile of viral and cellular genes for proliferation and apoptosis in AIDS-related lymphoma cells infected with Kaposi's sarcoma-associated virus. Biochem Biophys Res Commun, 287, 983–994.
27.
TanJ., YouY., XuT., YuP., WuD., DengH., et al. (2014). Par-4 downregulation confers cisplatin resistance in pancreatic cancer cells via PI3K/Akt pathway-dependent EMT. Toxicol Lett, 224, 7–15.
28.
von der MaaseH., SengelovL., RobertsJ.T., RicciS., DogliottiL., OliverT., et al. (2005). Long-term-survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol, 23, 4602–4608.
29.
WangY.X., JacobJ., WingfieldP.T., PalmerI., StahlS.J., KaufmanJ.D., et al. (2000). Anti-HIV and anti-tumor protein MAP30, a 30 kDa single-strand type-I RIP, shares similar secondary structure and beta-sheet topology with the A chain of ricin, a type-II RIP. Protein Sci, 9, 138–144.
30.
XuJ., CaoK., LiY., ZouX., ChenC., SzetoI.M.-Y., et al. (2014). Bitter gourd inhibits the development of obesity-associated fatty liver in C57BL/6 mice fed a high-fat diet. J Nutr 144,475.
31.
XueY.J., HanX.H., ChenD.Y., HuangH., LiX.Q., and ShaoS.H. (2011). Effects of recombinant MAP30 on cell proliferation and apoptosis of human esophageal carcinoma EC-1.71 cells. Afr J Pharm Pharmacol, 5, 2680–2688.
32.
ZhangD., ZhangH., HaoS., YanH., ZhangZ., HuY., et al. (2016). Akt specific activator SC79 protects against early brain injury following subarachnoid hemorrhage. ACS Chem Neurosci, 7, 710–718.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
